The National Security Commission on Emerging Biotechnology (NSCEB) announced on April 8, 2025, the availability of its final report and action plan, “urging Congressional action to bring the full ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Among other steps to foster international cooperation with our friends and partners, the report recommends that Congress include biotech within the scope of the State Department’s International ...

Biosecurity is changing its definition with the arrival of AI, now AI is rewriting the script of what Europe can do in biotechnology.

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T-cell ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

What’s next: The commission recommends the U.S. prioritize biotechnology ... that can replace federal government funding. The scope is slightly different. The U.S. government has a role in ...

Request To Download Free Sample of This Strategic Report  @   This country research report on Vietnam Market offers comprehensive insights into the market landscape, customer intelligence, and ...

However, in March, after settling a $30 million lawsuit over a data breach, 23andMe declared bankruptcy and announced they ...